Trial Profile

A Phase Ib/II Study of Pembrolizumab and Monoclonal Antibody Therapy in Patients With Advanced Cancer (PembroMab

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Cetuximab; Trastuzumab; Trastuzumab emtansine
Indications Solid tumours
Focus Adverse reactions

Most Recent Events

30 Oct 2018 Status changed from active, no longer recruiting to discontinued as PI is no longer at sight. Results not collected
24 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Dec 2018.
24 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jun 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com